Kalgene’s Series A marks start of Lumira Capital’s next chapter

3D medical background with male head with brain and DNA strands; Photo courtesy of kirstypargeter/iStock/Getty Images
This year has been eventful for Lumira Capital. The Toronto life-sciences investor held a first close for Fund IV, completed the fund’s debut deals, tied up investing by prior funds, and took a portfolio star public. One milestone was met in ...

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.